True Wealth Design
PLX icon

True Wealth Design’s Protalix BioTherapeutics PLX Stock Holding History

True Wealth Design’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-115
Closed -$268 – 2737
2026
Q2 		$268 Buy
115
+104
+945% +$220 ﹤0.01% 2387
2026
Q1 		$24 Buy
+11
New +$27 ﹤0.01% 2633

Other funds holding PLX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

True Wealth Design's PLX Position: Q3 2026 in Review

True Wealth Design sold out of Protalix BioTherapeutics (PLX) in Q3 2026, closing a stake of 115 shares — an estimated $268 sold.

True Wealth Design first reported a position in PLX in Q1 2026 and held it in 2 quarters. The position peaked at $268 in Q2 2026. 48 funds tracked by Wall St. Rank hold PLX as of Q3 2026.

  • True Wealth Design reported no remaining Protalix BioTherapeutics position as of Q3 2026 after selling out during the quarter.
  • True Wealth Design sold 115 Protalix BioTherapeutics shares in Q3 2026, an estimated $268.
  • True Wealth Design first reported a position in Protalix BioTherapeutics in Q1 2026 and held it in 2 quarters.
  • True Wealth Design's Protalix BioTherapeutics position peaked at $268 in Q2 2026.
  • 48 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.